![]() While it typically takes blockbuster drugs at least a year to reach $1 billion in annual sales, Trikafta nearly hit $1 billion in sales in the third quarter. Food and Drug Administration approximately five months ahead of schedule. ![]() The company's latest approved CF drug, Trikafta, got the green light from the U.S. While there's no cure, the mutation-specific treatments Vertex has developed are improving CF patients' quality of life. CF is a progressive genetic disease involving thick mucus production that can obstruct the lungs and pancreas. Vertex's key to success is the company's focus on treating patients with cystic fibrosis (CF). Vertex can be a big winner for patient investors, particularly since there's little chance of drug-pricing reforms under Biden. Vertex PharmaceuticalsĪmong healthcare stocks, few have more momentum than specialty drug developer Vertex Pharmaceuticals ( VRTX -1.49% ).
0 Comments
Leave a Reply. |